BTK inhibitors such as ibrutinib can cause an irregular heartbeat (atrial fibrillation), bleeding and bruising, and high blood pressure. Your team checks your pulse and blood pressure and reviews any blood thinners. The medicine may be paused around an operation or dental work. Report straight away a fast or irregular heartbeat, feeling faint, chest discomfort, or bleeding you cannot control.
Before a BTK inhibitor, take a cardiovascular history and record blood pressure and an ECG (both consensus statements; the ibrutinib label says to evaluate cardiac history and function at baseline), with an echocardiogram for people at high cardiovascular risk (ESC 2022 Class I, Level C). ESC recommends blood pressure at every visit (Class I, Level B) and a pulse check or ECG rhythm strip at every visit (Class I, Level C), and says home readings weekly for 3 months and then monthly should be considered (Class IIa, Level C).
On the choice of drug the sources differ. ESC 2022 says the data do not yet support different monitoring strategies for ibrutinib and acalabrutinib. Two consensus statements, both funded by AstraZeneca, the maker of acalabrutinib, prefer acalabrutinib or zanubrutinib to ibrutinib in people with established cardiovascular disease and advise against BTK inhibitors, especially ibrutinib, after ventricular arrhythmia or cardiac arrest. In the ELEVATE-RR trial atrial fibrillation of any grade occurred in 16 per cent on ibrutinib and 9 per cent on acalabrutinib. The ibrutinib label warns of fatal arrhythmias, cardiac failure and sudden death.
ESC says that neither atrial fibrillation nor the risk of it is a contraindication to cancer treatment. It says rate control, preferably with a beta-blocker, should be considered for well-tolerated atrial fibrillation (Class IIa, Level C), with diltiazem and verapamil avoided where possible. Long-term anticoagulation is recommended at a CHA2DS2-VASc score of 2 or more in men or 3 or more in women (ESC Class I, Level C) and should be considered at 1 in men or 2 in women (Class IIa, Level C), weighed against bleeding risk. ESC says a direct oral anticoagulant should be considered in preference to low molecular weight heparin and vitamin K antagonists such as warfarin, in people without a high bleeding risk, significant drug interactions or severe renal dysfunction (Class IIa, Level B). The Australia and New Zealand consensus says to avoid warfarin if possible because most BTK inhibitor trials excluded it (Class IIb, Level C) and to switch to a direct oral anticoagulant, preferably apixaban (Class IIa, Level C). The same consensus says dual antiplatelet therapy should generally be avoided (Class IIb, Level C), and ESC says ibrutinib should be temporarily interrupted in people who need it. All four labels say to consider withholding the drug for 3 to 7 days before and after surgery (the ibrutinib label says at least 3 to 7 days); the Australia and New Zealand consensus sets 3 days for minor and 7 days for major procedures (Class IIa, Level C). Bleeding from low platelets is covered by a separate protocol. This page explains care; the treating team's own protocol and the product's current label come first.
Why: The ibrutinib label says its serious heart rhythm problems happened particularly in people with high blood pressure, diabetes or a past arrhythmia, and it too asks for cardiac history and function to be evaluated at baseline. The schedule quoted here comes from a consensus statement funded by AstraZeneca.
“A thorough baseline CV risk assessment is recommended in all CLL patients prior to starting a BTKi (time permitting). This includes patient history (risk factors, comorbidities, pre‐existing CVD, previous cardiotoxic therapy), physical examination (BP, pulse) and 12‐lead ECG.”
Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 · Class I, Level B
Why: ESC counts as high risk: men, people aged 65 or over, and people with high blood pressure, diabetes, a long QT interval (QTc of 480 ms or more), atrial fibrillation, heart failure, cardiomyopathy or severe valve disease. The international consensus is more cautious and says an echocardiogram can be considered for people at high cardiovascular risk or with established cardiovascular disease.
“Baseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors.”
European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Class I, Level C
Why: BTK inhibitors raise the risk of bleeding on their own, and the labels say antiplatelet and anticoagulant medicines can raise it further. The same consensus, funded by AstraZeneca, asks teams to encourage people to avoid over-the-counter products such as vitamin E and fish oil (Class I, Level C).
“Where possible, avoid the use of antiplatelet therapies and other agents that increase the risk of bleeding (e.g. NSAIDs).”
Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 · Class I, Level C
Why: Trials comparing the drugs found less atrial fibrillation with the newer ones, but the ESC guideline says there are not yet enough data to set different monitoring, and the consensus statements that state the preference were funded by AstraZeneca, which makes acalabrutinib.
“acalabrutinib or zanubrutinib are generally preferred over ibrutinib for patients with established CVD, such as well-controlled AF, HTN, heart failure, or valvular heart disease”
Blood Advances (Awan et al.); project funded by AstraZeneca 2022
Why: The international consensus, funded by AstraZeneca, says ibrutinib has been shown to increase ventricular arrhythmias and sudden cardiac death, that it is not yet known whether the newer drugs do the same, and that it prefers a BCL-2 inhibitor to any BTK inhibitor here. The Australia and New Zealand consensus also says BTK inhibitors should generally be avoided after ventricular arrhythmia (Class III, Level C).
“The use of BTKis, especially ibrutinib, should be avoided in patients with a history of ventricular arrhythmias and cardiac arrest.”
Blood Advances (Awan et al.); project funded by AstraZeneca 2022
Why: Atrial fibrillation can cause no symptoms at all, so the guideline asks for a check at each visit rather than waiting for a complaint.
“Opportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy”
European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Class I, Level C
Why: High blood pressure occurred in 19 per cent of patients in the ibrutinib trials, and the ibrutinib label says to monitor it and to start or adjust blood pressure medicine as appropriate. ESC grades the home readings lower, as something that should be considered (Class IIa, Level C).
“BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.”
European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Class I, Level B
Why: The labels list these as the symptoms of a rhythm problem. The ibrutinib label says to obtain further evaluation, such as an ECG or echocardiogram, as indicated when they appear.
“Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately”
BeOne Medicines, on DailyMed (US National Library of Medicine) 2026
Why: ESC recommends an echocardiogram for everyone who develops atrial fibrillation on a BTK inhibitor (Class I, Level C) and a team decision on the cancer treatment. The international consensus says people with few other risk factors are often suitable to continue.
“neither the presence nor the risk of AF constitutes contraindications to anticancer treatment”
Why: ESC says rate control, preferably with a beta-blocker, should be considered (Class IIa, Level C). It gives drug interactions and a weakening effect on the heart's pumping as the reasons to avoid diltiazem and verapamil where possible.
“Among rate-control drugs, beta-blockers are preferred, especially if the cancer therapies have potential CTRCD risk, whereas diltiazem and verapamil should be avoided where possible due to their drug–drug interactions and negative inotropic effects”
Why: Atrial fibrillation raises the risk of stroke, and long-term anticoagulation is given to prevent it. ESC grades anticoagulation at the lower scores as something that should be considered (Class IIa, Level C), says the score may underestimate the risk in cancer, and recommends reassessing clot and bleeding risk during follow-up (Class I, Level C).
“Long-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a CHA2DS2-VASc score ≥2 (men) or ≥3 (women)”
European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Class I, Level C
Why: Most BTK inhibitor trials kept out people on warfarin, so there is little evidence that the combination is safe; this consensus, funded by AstraZeneca, prefers apixaban. ESC says a direct oral anticoagulant should be considered in preference to warfarin and heparin in people without a high bleeding risk, significant drug interactions or severe renal dysfunction (Class IIa, Level B).
“Most BTKi trials exclude warfarin use, so there are scant safety data supporting the co‐administration of these agents.”
Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025
Why: ESC gives a higher bleeding risk as the reason to interrupt ibrutinib. The Australia and New Zealand consensus, funded by AstraZeneca, says the combination should generally be avoided because safety data are limited (Class IIb, Level C) and that antiplatelet therapy should be as short as possible (Class I, Level C).
“Due to a higher bleeding risk, ibrutinib should be temporarily interrupted in patients requiring dual antiplatelet therapy (DAPT) and 3–7 days before invasive procedures.”
Why: These medicines raise the risk of bleeding around a procedure, and the ibrutinib label counts bleeding after a procedure among its major bleeding events. The labels tell patients the medicine may be stopped for a planned medical, surgical or dental procedure.
“Consider the benefit-risk of withholding CALQUENCE for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.”
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
Why: Fatal and serious bleeding has occurred with all four medicines. The ibrutinib label gives a similar list of signs to report (severe headache, blood in stools or urine, prolonged or uncontrolled bleeding).
“Tell your healthcare provider right away if you have any signs or symptoms of bleeding, including:”
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
Why: Each label sets its own rule for restarting at a lower dose or stopping for good.
“Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs.”
BeOne Medicines, on DailyMed (US National Library of Medicine) 2026
Why: Ventricular arrhythmias have been reported with BTK inhibitors, and the ibrutinib label warns of sudden death, including in people without known heart disease. This consensus was funded by AstraZeneca.
“An urgent cardiology review is required if VT is suspected at any time.”
Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The 2022 ESC cardio-oncology guideline is the only independent graded guideline read; its BTK inhibitor recommendations are Level B or C, and its atrial fibrillation recommendations are Level C apart from the one preferring direct oral anticoagulants (Level B). The four labels agree on monitoring for arrhythmia and bleeding and on considering a 3 to 7 day pause either side of surgery. The most detailed management advice comes from two consensus statements (international, 2022; Australia and New Zealand, 2025) that were both funded by AstraZeneca, the maker of acalabrutinib, and should be read with that in mind. Differences shown here: Choice of drug: ESC says there are not enough data to set different monitoring for ibrutinib and acalabrutinib; both consensus statements prefer acalabrutinib or zanubrutinib in people with cardiovascular disease. Time off around procedures: the labels say to consider 3 to 7 days before and after surgery; ESC says to interrupt ibrutinib 3 to 7 days before invasive procedures; the Australia and New Zealand consensus sets 3 days before and after a minor procedure and 7 days for a major one (Class IIa, Level C). Anticoagulant: ESC says a direct oral anticoagulant should be considered in preference to low molecular weight heparin and vitamin K antagonists in people without a high bleeding risk, significant drug interactions or severe renal dysfunction (Class IIa, Level B), and notes that their use in cancer is limited by drug interactions; the Australia and New Zealand consensus says to avoid warfarin if possible (Class IIb, Level C) and switch to a direct oral anticoagulant, preferably apixaban (Class IIa, Level C); the international consensus calls warfarin less preferred and says the data do not clearly support a single approach. Blood pressure medicine: ESC recommends an ACE inhibitor or ARB first for cancer therapy-related hypertension in general, while the international consensus reports an unconfirmed signal from the FLAIR trial linking ACE inhibitor use at entry with sudden cardiac death on ibrutinib, asks for close monitoring, and lists a medicine other than an ACE inhibitor in the first instance for new hypertension; the Australia and New Zealand consensus leaves the choice to local blood pressure guidelines and says medicines that interact with CYP3A4, such as diltiazem and verapamil, should generally be avoided (Class IIa, Level C).
European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Blood Advances (Awan et al.); project funded by AstraZeneca 2022 · Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 · Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · BeOne Medicines, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Where it differs: Uses a second-generation BTK inhibitor rather than ibrutinib in people with established cardiovascular disease, controlled atrial fibrillation or high cardiovascular risk; avoids BTK inhibitors, especially ibrutinib, after ventricular arrhythmia or cardiac arrest; and treats active heart failure as a relative contraindication.
Evidence: ELEVATE-RR (acalabrutinib against ibrutinib in previously treated CLL, as reported in the international consensus): atrial fibrillation of any grade in 16 per cent on ibrutinib and 9 per cent on acalabrutinib. ESC notes that grade 3 or higher atrial fibrillation, and atrial fibrillation in people aged 75 or over or with previous atrial fibrillation, were comparable between the groups. Both consensus statements were funded by AstraZeneca, the maker of acalabrutinib; the international one states that all authors received funding from AstraZeneca for the work and thanks a named person at a company for assistance in preparing the manuscript.
Blood Advances (Awan et al.); project funded by AstraZeneca 2022 · Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 · European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022
Where it differs: Labels: consider withholding for 3 to 7 days before and after surgery (ibrutinib: at least 3 to 7 days). ESC: interrupt ibrutinib 3 to 7 days before invasive procedures, and consider platelet transfusion for emergency interventions. Australia and New Zealand consensus: 3 days before and after a minor procedure, 7 days before and after a major one.
Evidence: Label wording and consensus (Class IIa, Level C in the Australia and New Zealand statement). None of the sources read cites a trial comparing durations.
Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · BeOne Medicines, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025
Where it differs: Australia and New Zealand consensus: avoid warfarin if possible, switch to a direct oral anticoagulant, preferably apixaban because it has the fewest interactions, and consider a reduced dose if bleeding risk is high; warfarin remains necessary for mechanical heart valves. International consensus: warfarin is less preferred, and the data do not clearly support a single approach between stopping the BTK inhibitor and anticoagulating, or pausing and restarting once atrial fibrillation is controlled. ESC: follow the general atrial fibrillation guideline, using the T (thrombotic risk), B (bleeding risk), I (interactions), P (patient access and preferences) approach; a direct oral anticoagulant should be considered in preference to low molecular weight heparin and vitamin K antagonists in people without a high bleeding risk, significant drug interactions or severe renal dysfunction, and vitamin K antagonists remain the only anticoagulants indicated with a mechanical valve or moderate to severe mitral stenosis.
Evidence: The ibrutinib label reports major haemorrhage in 3.1 per cent of patients without antiplatelet or anticoagulant therapy, 4.4 per cent with antiplatelet therapy and 6.1 per cent with anticoagulant therapy. ESC grades its preference for direct oral anticoagulants Class IIa, Level B and says they have not been tested for atrial fibrillation in a dedicated randomised trial in people with cancer. None of the sources read cites a randomised trial of an anticoagulant given with a BTK inhibitor.
Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 · Blood Advances (Awan et al.); project funded by AstraZeneca 2022 · European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 · Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025
Where it differs: Ibrutinib: interrupt until the problem has improved to grade 1 or baseline; after a first grade 3 arrhythmia weigh benefit against risk and restart at a reduced dose, stop after a second, and stop after any grade 4 arrhythmia or grade 3 or 4 cardiac failure; grade 2 cardiac failure has its own stepped reductions. Pirtobrutinib: reduce, withhold or stop by severity. Zanubrutinib: monitor for symptoms, manage appropriately and consider the risks and benefits of continuing. Acalabrutinib: monitor for symptoms and manage as appropriate.
Evidence: Regulatory labels, not graded.
Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · BeOne Medicines, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Blood pressure measured at every clinical visit on BTK inhibitors | Class I, Level B | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Weekly home blood pressure for the first 3 months and monthly thereafter | Class IIa, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Baseline echocardiography in high-risk patients scheduled to receive BTK inhibitors | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Transthoracic echocardiography in all patients who develop atrial fibrillation on a BTK inhibitor | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Pulse check or ECG rhythm strip for atrial fibrillation at every clinical visit on a BTK inhibitor | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| CHA2DS2-VASc score for stroke risk, bearing in mind it may underestimate risk in cancer | Class IIa, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Long-term anticoagulation at a CHA2DS2-VASc score of 2 or more in men or 3 or more in women | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Long-term anticoagulation should be considered at a CHA2DS2-VASc score of 1 in men or 2 in women | Class IIa, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| A direct oral anticoagulant should be considered in preference to low molecular weight heparin and vitamin K antagonists, in people without a high bleeding risk, significant drug interactions or severe renal dysfunction and excluding mechanical heart valves and moderate to severe mitral stenosis | Class IIa, Level B | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Rate control, preferably with beta-blockers, should be considered for well-tolerated atrial fibrillation during active cancer treatment | Class IIa, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Reassessment of thromboembolic and bleeding risk during follow-up | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| ESC: not enough data to set different monitoring for ibrutinib and acalabrutinib “Therefore, we currently do not have enough data to establish different monitoring strategies in patients treated with these drugs.” | Guideline text; not graded | European Society of Cardiology (European Heart Journal); read from the published PDF held by an institutional repository 2022 |
| Baseline history, blood pressure, pulse and 12-lead ECG for everyone before a BTK inhibitor (statement funded by AstraZeneca) | Class I, Level B | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Avoid antiplatelet therapies and other agents that increase bleeding where possible (statement funded by AstraZeneca) | Class I, Level C | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Dual antiplatelet therapy generally avoided (statement funded by AstraZeneca) “Dual anti‐platelet therapy should generally be avoided wherever possible, given the limited data on safety and the increased risk of bleeding.” | Class IIb, Level C | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Withhold for 3 days either side of a minor procedure and 7 days either side of a major one (statement funded by AstraZeneca) “Withhold the BTKi for 3 days before and 3 days after a minor procedure (or 7 days before and after a major procedure) because of an increased periprocedural bleeding risk.” | Class IIa, Level C | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Avoid warfarin if possible (Class IIb, Level C); switch to a direct oral anticoagulant, preferably apixaban (Class IIa, Level C) (statement funded by AstraZeneca) | Class IIb, Level C and Class IIa, Level C | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Initial rate control with beta-blockers is acceptable (statement funded by AstraZeneca) “In general, an initial strategy of rate control with beta blockers is acceptable.” | Consensus text; not graded | Internal Medicine Journal; roundtable and medical writing funded by AstraZeneca, Australia 2025 |
| Warfarin is less preferred with BTK inhibitors (statement funded by AstraZeneca) “Clinical trials routinely exclude warfarin, and warfarin is less preferred in patients receiving BTKis” | Consensus text; not graded | Blood Advances (Awan et al.); project funded by AstraZeneca 2022 |
| An echocardiogram can be considered for people at high cardiovascular risk or with established cardiovascular disease (statement funded by AstraZeneca) “Beyond these basic measures, an echocardiogram can be considered for patients with high CV risk or established CV disease.” | Consensus text; not graded | Blood Advances (Awan et al.); project funded by AstraZeneca 2022 |
| Pretreatment history, examination, ECG and blood pressure for everyone (statement funded by AstraZeneca) “The pretreatment workup for all patients should include a comprehensive patient history and targeted CV examination, including an electrocardiogram (ECG) and a blood pressure measurement to identify the main risk factors present, including AF and HTN” | Consensus text; not graded | Blood Advances (Awan et al.); project funded by AstraZeneca 2022 |
| Ibrutinib: fatal and serious arrhythmias, cardiac failure and sudden death “Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA.” | Regulatory label; not graded | Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 |
| Ibrutinib: evaluate cardiac history and function at baseline “Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function.” | Regulatory label; not graded | Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 |
| Ibrutinib: monitor blood pressure and start or adjust blood pressure medicine “Monitor blood pressure in patients treated with IMBRUVICA, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension” | Regulatory label; not graded | Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 |
| Ibrutinib: signs of bleeding for patients to report “Inform patients of the possibility of bleeding, and to report any signs or symptoms (severe headache, blood in stools or urine, prolonged or uncontrolled bleeding).” | Regulatory label; not graded | Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 |
| Ibrutinib: consider withholding for at least 3 to 7 days before and after surgery “Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding” | Regulatory label; not graded | Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 |
| Pirtobrutinib: consider withholding for 3 to 7 days before and after surgery “Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.” | Regulatory label; not graded | Eli Lilly, on DailyMed (US National Library of Medicine) 2026 |
| Zanubrutinib: consider withholding for 3 to 7 days before and after surgery “Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding.” | Regulatory label; not graded | BeOne Medicines, on DailyMed (US National Library of Medicine) 2026 |
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Drug, herbal and food interaction review for anticancer treatment, Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy) and the tags protocol, cardio-oncology, side-effect-management.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology and the tags protocol, cardio-oncology.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), European Society for Medical Oncology (ESMO) and the tags protocol, cardio-oncology.
Shares Pirtobrutinib, Zanubrutinib, Acalabrutinib, Ibrutinib.
Shares European Society for Medical Oncology (ESMO) and the tag protocol.
Shares Caution: ibrutinib in patients with cardiac risk, Zanubrutinib, BTK (Bruton tyrosine kinase), Ibrutinib.
Shares Pirtobrutinib, Zanubrutinib, Acalabrutinib, BTK (Bruton tyrosine kinase).
Shares European Society for Medical Oncology (ESMO) and the tag protocol.